Mobile

Combination chemotherapy mFOLFOX6 versus combination chemotherapy and Aflibercept in patients with locally advanced rectal cancer staged T3 in MRI Kombinationschemotherapie mFOLFOX6 vs. Kombinat...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-002773-38

Combination chemotherapy mFOLFOX6 versus combination chemotherapy and Aflibercept in patients with locally advanced rectal cancer staged T3 in MRI Kombinationschemotherapie mFOLFOX6 vs. Kombinationschemotherapie mFOLFOX6 + Aflibercept als neoadjuvante Behandlung von Patienten mit wanddurchsetzendem Rektumkarzinom (Stadium T3, im MRT bestimmt): eine randomisierte Phase II- Studie

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate the pathological tumor response based on central pathologic review of the mFOLFOX6/aflibercept combination as compared to mFOLFOX6 alone in patients with locally advanced rectal cancer staged cT3 CRM-negative with MRI.

Critère d'inclusion

  • Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI

Liens